Clearside Biomedical Inc reports results for the quarter ended June 30 - Earnings Summary

Clearside Biomedical,

12/08/2025 15:12

Clearside Biomedical Inc CLSD.OQ reported a quarterly adjusted loss of 6 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -10 cents.  The mean expectation of seven analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -12 cents to -7 cents per share.

Revenue rose 446.7% to $492.00 thousand from a year ago; analysts expected $170.00 thousand.

Clearside Biomedical Inc's reported EPS for the quarter was a loss of 6 cents​.

The company reported a quarterly loss of $4.5 million.

Clearside Biomedical Inc shares had fallen by 49.6% this quarter and lost 57.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 8.2% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."

Wall Street's median 12-month price target for Clearside Biomedical Inc is $5.00, about 91.9% above its last closing price of $0.40

This summary was machine generated from LSEG data August 12 at 02:11 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.10
-0.06
Beat
Mar. 31 2025
-0.11
-0.11
Met
Dec. 31 2024
-0.10
-0.10
Met
Sep. 30 2024
-0.12
-0.10
Beat